Press Releases

Date Title and Summary Additional Formats
Toggle Summary ProTmune™ Investigational New Drug Application for Prevention of Acute GvHD and CMV Infection Cleared by FDA in January 2016 Phase 1/2 Clinical Trial of ProTmune to Commence Enrollment in mid-2016 Data Updates for All Preclinical Adoptive Immunotherapy Programs Expected in 1H16 SAN DIEGO, Read All » View HTML
Toggle Summary SAN DIEGO, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Read All » View HTML
Toggle Summary Poster Presentation to Highlight Anti-Tumor Properties of Ex Vivo Programmed Donor T Cells Phase 1/2 Clinical Trial of ProTmune in Mobilized Peripheral Blood HCT to Commence Enrollment in Mid-2016 SAN DIEGO, Feb. 21, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All » View HTML
Toggle Summary SAN DIEGO, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be Read All » View HTML
Toggle Summary Multi-Center, Randomized, Controlled Phase 1/2 Clinical Trial in Mobilized Peripheral Blood HCT to be Initiated in Mid-2016 Read All » View HTML
Toggle Summary SAN DIEGO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Read All » View HTML
Toggle Summary Supportive Interim Data from ProHema® PUMA Study Demonstrate the Therapeutic Potential of Programmed Donor Cells Clinical Development Strategy to Focus on Prevention of Life-Threatening Complications in Mobilized Peripheral Blood HCT ProTmune™ to Advance into Phase 1/2 Clinical Trial for Read All » View HTML
Toggle Summary SAN DIEGO , Dec. 3, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All » View HTML
Toggle Summary Proprietary Pluripotent Cell Platform for Engineered Adoptive Immunotherapies to be Highlighted During Two Poster Sessions Read All » View HTML
Toggle Summary First-in-Human Clinical Trial to Prevent Acute Graft-versus-Host Disease and Severe Infections Planned for 2016 Poster Presentations to Highlight Preclinical Findings and Potential Therapeutic and Pharmacoeconomic Value Propositions in HCT SAN DIEGO, Nov. Read All » View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.